ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses25.89 M28.18 M35.53 M49.84 M52.27 M165.81 MResearch & development61.91 M66.57 M76.24 M80.3 M90.46 M313.57 MOperating income87.8 M94.75 M111.41 M129.11 M142.59 M477.85 MNon-Operating Income, Total10.97 M14.15 M14.63 M13.47 M12.49 M54.75 MInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses10.97 M14.15 M14.63 M13.47 M12.45 M54.7 MUnusual income/expense————49 K—Pretax income98.77 M298.41 M126.04 M142.59 M130.09 M697.12 MEquity in earnings————0—Taxes—153.01 M————Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations76.83 M80.59 M96.77 M115.64 M130.09 M423.1 MDiscontinued operations——————Net income76.83 M80.59 M96.77 M115.64 M130.09 M423.1 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders76.83 M80.59 M96.77 M115.64 M130.09 M423.1 MBasic earnings per share (Basic EPS)-0.96-0.86-1.04-1.23-1.38-4.51Diluted earnings per share (Diluted EPS)-0.96-0.86-1.04-1.23-1.38-4.51Average basic shares outstanding80.09 M80.78 M93.1 M93.79 M94.22 M361.89 MDiluted shares outstanding80.09 M80.78 M93.1 M93.79 M94.22 M361.89 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)-3.51 M-4.16 M-4.38 M-4.71 M-3.6 M-16.85 M
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.